Stockscreener 앱 받기
3.11
1.97%
0.06
시간 외 거래:
3.11
전일 마감가:
$3.05
열려 있는:
$3.14
하루 거래량:
15,320
Relative Volume:
0.50
시가총액:
$313.17M
수익:
$68.15M
순이익/손실:
$-67.60M
주가수익비율:
-4.6177
EPS:
-0.6735
순현금흐름:
$-41.80M
1주 성능:
+12.68%
1개월 성능:
+18.25%
6개월 성능:
-19.85%
1년 성능:
+9.12%
1일 변동 폭
$2.95
$3.1752
1주일 범위
$2.80
$3.18
52주 변동 폭
$2.35
$5.4796
Cellectis Adr Stock (CLLS) Company Profile
Compare CLLS vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLLS
Cellectis Adr
|
3.11 | 307.13M | 68.15M | -67.60M | -41.80M | -0.6735 |
VRTX
Vertex Pharmaceuticals Inc
|
515.55 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.93 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
987.84 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.00 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.51 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cellectis Adr Stock (CLLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-17 | 재개 | Jefferies | Buy |
| 2023-03-17 | 개시 | Bryan Garnier | Buy |
| 2022-05-18 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-01-06 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2021-11-30 | 개시 | JMP Securities | Mkt Outperform |
| 2021-11-08 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-10-08 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2021-04-28 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-03-16 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2020-08-19 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-05-12 | 개시 | Robert W. Baird | Outperform |
| 2020-03-06 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-10-30 | 재개 | Guggenheim | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-05-24 | 재개 | Citigroup | Neutral |
| 2019-03-14 | 개시 | William Blair | Outperform |
| 2018-12-19 | 개시 | Goldman | Neutral |
| 2018-07-16 | 개시 | Barclays | Overweight |
| 2018-03-16 | 개시 | Guggenheim | Neutral |
| 2017-09-05 | 다운그레이드 | SunTrust | Buy → Hold |
| 2017-09-05 | 재확인 | Wells Fargo | Outperform |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2017-02-28 | 개시 | Wells Fargo | Outperform |
| 2016-04-05 | 개시 | Ladenburg Thalmann | Buy |
| 2016-03-02 | 개시 | Sun Trust Rbsn Humphrey | Buy |
| 2015-07-20 | 개시 | BofA/Merrill | Buy |
| 2015-04-20 | 개시 | Jefferies | Buy |
| 2015-04-20 | 개시 | Piper Jaffray | Overweight |
모두보기
Cellectis Adr 주식(CLLS)의 최신 뉴스
Cellectis earnings beat by $0.04, revenue fell short of estimates - Investing.com
Cellectis S.A. Sponsored ADR Revenue Breakdown – LS:A14QZE - TradingView
European ADRs Traded Higher In US Morning Session - Finimize
ETFs Investing in Cellectis S.A. Sponsored ADR Stocks - TradingView
Multiple Myeloma Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics, Poseida Therapeutics - Barchart.com
European ADRs Jumped As Biotech Led The Pack - Finimize
Cellectis S.A. Sponsored ADR Financial Disclosures & SEC Filings - TradingView
European ADRs Rose As Biopharma Names Led The Pack - Finimize
A14QZE Forecast — Price Target — Prediction for 2027 - TradingView
Cellectis S.A. Sponsored ADR Actuals & Estimates (NASDAQ:CLLS) - TradingView
symbol__ Stock Quote Price and Forecast - CNN
European ADRs Slip, Even As Biotech Names Edge Higher - Finimize
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress - GlobeNewswire Inc.
Cellectis stock rises on FDA therapy designation - Investing.com
Cellectis stock rises on FDA therapy designation By Investing.com - Investing.com India
CLLS Stock Chart | CELLECTISADR (NASDAQ:CLLS) - ChartMill
Barclays initiates Cellectis stock with overweight, $9 target - Investing.com
CLLSCellectis ADR Stock Price and Quote - Finviz
Cellectis’s SWOT analysis: biotech stock shows promise in CAR-T therapy - Investing.com
CLLS Stock Price, Quote & Chart | CELLECTISADR (NASDAQ:CLLS) - ChartMill
Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress - ChartMill
Cellectis Reports Financial Results for the First Quarter 2026 - ChartMill
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting - ChartMill
European ADRs Open Lower As Telecoms And Biotech Split - Finimize
Cellectis stock rating held at outperform on allogeneic platform - Investing.com
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform - ChartMill
European ADRs Headed For A Strong Week In US Trading - Finimize
Monthly information on share capital and company voting rights - ChartMill
Citizens reiterates Cellectis stock rating on CAR-T progress By Investing.com - Investing.com South Africa
Cellectis earnings beat by $0.10, revenue topped estimates - Investing.com
Earnings call transcript: Cellectis beats Q4 2025 forecasts, stock rises - Investing.com
Cellectis (NASDAQ: CLLS) 2025 annual report shows losses and funding runway - Stock Titan
Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update - ChartMill
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 - ChartMill
European ADRs Slipped As Biopharma Dragged The Pack - Finimize
European ADRs Rose In US Trading, Led By HSBC And Sequans - Finimize
European ADRs Slipped To Start The Week, With Pharma Leading Moves - Finimize
Cellectis Adr (CLLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
1.77%
자본화:
|
볼륨(24시간):